ImmuneSense Lyme Study

Adaptive Biotechnologies

Status: Completed

Conditions: Lyme Disease

Treatments: Diagnostic Test: T-Detect Lyme

Study type: Observational

Funder types: Industry

Identifiers

NCT04422314

PRO-00717

Details and patient eligibility

About

ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. Data collected from this study may accelerate the development of better diagnostics for Lyme disease and improve outcomes for many.

Enrollment: 893 patients

Sex: All

Ages: 7+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Cohort 1:

• Participants at or above the age of 7
• Arm A: Participants with an EM rash ≥ 5 cm (confirmed by Lyme disease independent expert) with or without other signs and symptoms of Lyme disease
• Arm B: Participants who do not have an EM rash >/= 5 cm (either not confirmed by a Lyme disease independent expert or lacking a rash), but who have signs and symptoms suggestive of Lyme disease that warrants further testing, such as, but not limited to fever, myalgias, malaise, lymphadenopathy, rigors, arthralgias, peripheral and radiculoneuropathy, encephalopathy, intermittent arthritis, meningitis, heart block, carditis, etc

Cohort 2:

• Individuals in general good health, who reside in Lyme disease endemic regions

Cohort 3:

• Individuals in general good health, who reside in a region that is non-endemic for Lyme disease

Cohort 4:

Sourced from a sample repository

• Biorepositories with documented consent from participants for secondary use of their sample by a third party
• Confirmed, documented diagnoses for one of the following diseases:
• Viral: Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza, or COVID-19
• Tick-borne diseases: babesiosis, rocky mountain spotted fever, anaplasmosis, or ehrlichiosis
• Bacterial infection: syphilis
• Autoimmune/rheumatologic/neurologic diseases: Systemic Lupus Erythematous (SLE), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), chronic fatigue syndrome
• For infections, active infections are preferred and should be prioritized. Past infections will be acceptable for infections that are difficult to obtain.

Prospective collection Inclusion criteria

• Confirmed, documented diagnoses for one of the following diseases:
• Viral: Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza, or COVID-19
• Tick-borne diseases: babesiosis, rocky mountain spotted fever, anaplasmosis, or ehrlichiosis
• Bacterial infection: syphilis
• Autoimmune/rheumatologic/neurologic diseases: Systemic Lupus Erythematous (SLE), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), or chronic fatigue syndrome
• For infections, active infections are preferred and should be prioritized. Past infections will be acceptable for infections that are difficult to obtain.

Cohort 5:

• Participants ages 18 and above
• Arm A: Participants with an EM rash ≥ 5 cm (confirmed by Lyme disease independent expert) with or without other signs and symptoms of Lyme disease
• Arm B: Participants who do not have an EM rash >/= 5 cm (either not confirmed by a Lyme disease independent expert or lacking a rash), but who have signs and symptoms suggestive of Lyme disease that warrants further testing, such as, but not limited to fever, myalgias, malaise, lymphadenopathy, rigors, arthralgias, peripheral and radiculoneuropathy, encephalopathy, intermittent arthritis, meningitis, heart block, carditis, etc

Exclusion criteria

• Participants will be excluded from the study if they meet any of the following criteria:
• Participant is a pregnant woman, prisoner, mentally disabled person, or ward-of-the state.
• Participant has any significant condition, laboratory abnormality, or psychiatric illness that would prevent the participant from safely participating in the study.
• Participant has been exposed to an investigational drug (new chemical entity) within 60 days prior to enrollment at the discretion of the investigator.
• Participant has donated more than one pint or 500cc of blood in the past two months or weight-based limits for pediatric populations.
• Received the Lyme disease vaccine
• Chronic infection with HIV, Tuberculosis, Hepatitis C, or Hepatitis B
• Active malignancy

Trial design

893 participants in 5 patient groups

Cohort 1

Description:

Lyme disease testing cohort

Treatment:

Diagnostic Test: T-Detect Lyme

Cohort 2

Description:

Endemic, asymptomatic controls

Treatment:

Diagnostic Test: T-Detect Lyme

Cohort 3

Description:

Non-endemic, asymptomatic controls

Treatment:

Diagnostic Test: T-Detect Lyme

Cohort 4

Description:

Potential cross-reactive disease states

Treatment:

Diagnostic Test: T-Detect Lyme

Cohort 5

Description:

Lyme disease testing cohort

Treatment:

Diagnostic Test: T-Detect Lyme